Use of hcp sh2 specific compounds to enhance erythropoiesis

Details Use of hcp sh2 specific compounds to enhance erythropoiesis Use of hcp sh2 specific compounds to enhance erythropoiesis

A - Human Necessities

61

K

A61K 31/50 (2006.01) A61K 31/00 (2006.01) A61K 31/12 (2006.01) A61K 31/165 (2006.01) A61K 31/166 (2006.01) A61K 31/195 (2006.01) A61K 31/40 (2006.01) A61K 31/437 (2006.01) A61K 31/445 (2006.01) A61K 31/546 (2006.01) C07K 14/82 (2006.01) G01N 33/573 (2006.01)

Patent

CA 2169132

Invented is a method of enhancing erythropoiesis in a subject which comprises administering to the subject a therapeutically effective amount of a compound which binds to the human hcp SH2 domain with a binding affinity greaterthan fifty-fold higher than the binding affinity with which the compound binds to a human SH-PTP2SH2 domain, and, binds to a human src SH2 domain, a human lck SH2 domain, a human fyn SH2 domain and a human p85 SH2 domain with a binding affinity which is greater than fifty-fold lower than the binding affinity with which the compound binds to such hcp SH2 domain.

Affiliated with

Also associated with

Rating

Use of hcp sh2 specific compounds to enhance erythropoiesis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of hcp sh2 specific compounds to enhance erythropoiesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of hcp sh2 specific compounds to enhance erythropoiesis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1878770